TSE:4502Pharmaceuticals
Takeda’s New Low-IgA Immunoglobulin Launch: What Does It Reveal About Its Moat (TSE:4502)?
Takeda recently announced the U.S. availability of GAMMAGARD LIQUID ERC, a ready-to-use 10% low-IgA immunoglobulin therapy approved as replacement treatment for primary immunodeficiency in patients aged two and older, deliverable intravenously or subcutaneously.
This launch reinforces Takeda’s specialized position in immunoglobulin therapies, as it remains the only manufacturer offering a low-IgA 10% solution while planning to retire GAMMAGARD S/D by the end of December 2027.
Next, we’ll...